Developing DNA methylation-based prognostic biomarkers of acute myeloid leukemia

Journal of Cellular Biochemistry
Chundi GaoChanggang Sun

Abstract

Acute myeloid leukemia (AML) is a heterogeneous clonal neoplasm characterized by complex genomic alterations. The incidence of AML increases with age, and most cases experience serious illness and poor prognosis. To explore the relationship between abnormal DNA methylation and the occurrence and development of AML based on the Gene Expression Database (GEO), this study extracted data related to methylation in AML and identified a methylated CpG site that was significantly different in terms of expression and distribution between the primary cells of AML patients, and hematopoietic stem/progenitor cells from normal bone marrow. To further investigate the differences caused by the dysfunction of methylation sites, bioinformatics analysis was used to screen methylation-related biomarkers, and the potential prognostic genes were selected by univariate and multivariate Cox proportional hazards regressions. Finally, five independent prognostic indicators were identified. In addition, these results provide new insight into the molecular mechanisms of methylation.

References

Feb 24, 2001·Nature·P A Jones
Mar 27, 2002·Nature Reviews. Immunology·Bernhard HomeyAlbert Zlotnik
Jan 6, 2005·Respiratory Research·Daniel DroemannTorsten Goldmann
Feb 5, 2005·American Journal of Epidemiology·L GennariR Nuti
Mar 10, 2005·British Journal of Haematology·Daisuke HasegawaTatsutoshi Nakahata
Jun 21, 2005·The International Journal of Biochemistry & Cell Biology·Lucia AltucciHinrich Gronemeyer
Oct 23, 2008·Nucleic Acids Research·Tanya BarrettRon Edgar
Jan 10, 2009·Nature Protocols·Da Wei HuangRichard A Lempicki
Jun 18, 2010·The New England Journal of Medicine·Connie J Eaves, R Keith Humphries
Jul 6, 2010·Nucleic Acids Research·Kai WangHakon Hakonarson
Oct 6, 2010·Advances in Genetics·Marta Kulis, Manel Esteller
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Sep 24, 2011·Nature Reviews. Cancer·Stephen B Baylin, Peter A Jones
Jun 22, 2012·Journal of Medical Genetics·Xiao Chang, Kai Wang
Sep 28, 2012·Current Opinion in Oncology·Gail J Roboz
Jan 1, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ni-sha WangWen-ling Zheng
Jan 1, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Mar 4, 2014·Epigenomics·Kimberly WalterDavid S Shames
May 14, 2014·Cancers·Amy L RymaszewskiHaris G Vikis
Sep 18, 2014·The Journal of Obstetrics and Gynaecology Research·Wen-Yan ChenLu-Xing Zhong
Oct 30, 2014·Nucleic Acids Research·Damian SzklarczykChristian von Mering
Dec 5, 2014·Genome Medicine·Tania WitteClarissa Gerhauser
Jun 17, 2015·Epigenomics·Tomomitsu Tahara, Tomiyasu Arisawa
May 11, 2016·Advances in Experimental Medicine and Biology·Thierry Capiod
Nov 3, 2016·American Journal of Hematology·Courtney D DinardoStephen R Master
Dec 9, 2016·Prague Medical Report·Arda IsikDeniz Firat
Jul 27, 2017·Journal of Hematology & Oncology·Felix S LichteneggerMarion Subklewe
Nov 13, 2017·Matrix Biology : Journal of the International Society for Matrix Biology·Achilleas D Theocharis, Nikos K Karamanos

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Motoshi Ichikawa, Mineo Kurokawa
Nihon rinsho. Japanese journal of clinical medicine
Takashi Nagasawa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Leandro Cerchietti, Ari Melnick
© 2022 Meta ULC. All rights reserved